| abstract |
The invention belongs to the field of biotechnology, and discloses the application of a glycolysis pathway key enzyme in infantile hemangioma. The glycolysis pathway key enzyme is highly expressed in IH proliferation stage tissue and hemangioma endothelial cells, and inhibits the key enzyme The activity of phosphofructokinase-2/fructose-2,6-bisphosphatase 3 can inhibit the proliferation and migration of HemEC and promote apoptosis. Identification methods include: immunohistochemical analysis of the expression of key enzymes of glycolysis in proliferative and involutionary tissues of IH, analysis of the expression in HemEC and umbilical vein endothelial cells, and detection of HemEC proliferation, proliferation, and PFKFB3 expression after inhibitor intervention. Migration and apoptosis capacity. The invention determines the expression situation and function of key enzymes of glycolysis pathway in IH, reveals the pathological mechanism of IH occurrence and development, and provides experimental basis for IH treatment with glycolysis as the target. |